Biotech Bulls & Breakthroughs cover art

Biotech Bulls & Breakthroughs

Biotech Bulls & Breakthroughs

Written by: BioPharmCatalyst
Listen for free

LIMITED TIME OFFER | Get 2 Months for ₹5/month

About this listen

Welcome to Biotech Bulls & Breakthroughs! This brand new podcast from BioPharmCatalyst explores the dynamic world of biotech investing alongside long-time biotech trader Sheff from Sheff Station. Each month, we will be discussing current events in the biotech industry and how these events impact investors, as well as a discussion of upcoming catalysts in the biotech space.

© 2026 Biotech Bulls & Breakthroughs
Biological Sciences Economics Personal Finance Politics & Government Science
Episodes
  • Tackling Rare Genetic Diseases with Diagonal Therapeutics
    Mar 10 2026

    In this episode, John Gagliano speaks with Eric Duhaime, Senior VP of Finance and Corporate Development at Diagonal Therapeutics, about the innovative approaches the company is taking in drug development, with a particular focus on clustering agonist antibodies and rare genetic diseases. Eric shares his journey in biotech, the mission of Diagonal Therapeutics, and insights into the current biotech market trends. The conversation also covers the company's pipeline, their strategic use of health data to prove commercial viability, and their novel bispecific antibodies, highlighting the importance of tackling the root causes of diseases like Hereditary Hemorrhagic Telangiectasia (HHT).

    📲 Follow Eric Duhaime in Diagonal Therapeutics: https://www.linkedin.com/company/diagonal-therapeutics
    https://diagonaltx.com/

    In this episode:
    🔹 Novel antibodies for rare diseases.
    🔹 Restoring normal intracellular signaling pathways.
    🔹 Navigating the current biotech market.

    🧭 Track upcoming catalysts: https://www.biopharmcatalyst.com/calendars/fda-calendar
    🎧 Listen to more episodes: https://www.biopharmcatalyst.com/podcast
    📈 See Sheff’s Watchlist: https://www.biopharmcatalyst.com/sheffs-trades

    📲 Follow BioPharmCatalyst: https://x.com/BPharmCatalyst
    📲 Follow Sheff: https://x.com/SheffStation

    Disclaimer: BioPharmCatalyst is not a registered investment advisory firm and the views on this podcast are not to intended to be financial advice. The stocks discussed in this podcast may be held in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions.

    Show More Show Less
    20 mins
  • Talking Biotech: Biotech Stocks to Watch, Hedge Funds & More
    Feb 21 2026

    In this episode, as the biotech earnings season continues, John Gagliano and Sheff Sheffield explore the importance of cash burn in biotech, the role of hedge funds, and the many catalysts expected by the end of the quarter.

    In this episode:
    🔹 The importance of Cash in biotech.
    🔹 How hedge funds' 13-F filings influence biotech stocks.
    🔹 Companies relocating production to the US.

    🧭 Track upcoming catalysts: https://www.biopharmcatalyst.com/calendars/fda-calendar
    🎧 Listen to more episodes: https://www.biopharmcatalyst.com/podcast
    📈 See Sheff’s Watchlist: https://www.biopharmcatalyst.com/sheffs-trades

    📲 Follow BioPharmCatalyst: https://x.com/BPharmCatalyst
    📲 Follow Sheff: https://x.com/SheffStation

    Disclaimer: BioPharmCatalyst is not a registered investment advisory firm and the views on this podcast are not to intended to be financial advice. The stocks discussed in this podcast may be held in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions.

    Show More Show Less
    1 hr and 15 mins
  • Navigating the Future of Biotech: Insights from the JP Morgan Healthcare Conference 2026
    Jan 22 2026

    In this episode, as the biotech landscape continues to evolve, the recent JP Morgan Healthcare Conference 2026 has set the stage for an exciting year ahead. John Gagliano and Sheff Sheffield delve into the key takeaways from the conference, exploring significant acquisitions, emerging trends, and the role of artificial intelligence in shaping the industry's future.

    In this episode:
    🔹 Growth areas in immunology, metabolism, neurology, and oncology will drive the industry forward in 2026.
    🔹 China’s growing role in the market necessitates collaboration with U.S. companies for enhanced innovation.
    🔹 AI is becoming a transformative force in biotech, expediting drug discovery and product development.

    Sheff is proud to support the Northwest Association for Blind Athletes. Join us in empowering life-changing opportunities for visually impaired youth and adults through sports and community engagement. You can support this as well in the link below:
    Support NWABA: https://nwaba.org/support/other-ways-to-help/sheffstation/#join-sheff-station

    🧭 Track upcoming catalysts: https://www.biopharmcatalyst.com/calendars/fda-calendar
    🎧 Listen to more episodes: https://www.biopharmcatalyst.com/podcast
    📈 See Sheff’s Watchlist: https://www.biopharmcatalyst.com/sheffs-trades

    📲 Follow BioPharmCatalyst: https://x.com/BPharmCatalyst
    📲 Follow Sheff: https://x.com/SheffStation

    Disclaimer: BioPharmCatalyst is not a registered investment advisory firm and the views on this podcast are not to intended to be financial advice. The stocks discussed in this podcast may be held in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions.

    Show More Show Less
    50 mins
No reviews yet